中等度から重度の活動性クローン病の成人参加者の治療における経口エトラシモドの有効性と安全性を評価する研究 (CULTIVATE)
中等度から重度の活動性クローン病の導入および維持療法としての経口エトラシモドの有効性と安全性を評価するための多施設無作為化二重盲検並行群間研究
調査の概要
詳細な説明
この研究には 5 つのサブ研究が含まれています。
サブスタディ A - 第 2 相:中等度から重度の CD 患者における経口エトラシモド療法の安全性、忍容性、および有効性を評価するための第 2 相無作為化二重盲検サブスタディで、導入および維持用量の選択をサポートします。サブスタディ A は現在、登録を締め切られています。
サブスタディ 1 - フェーズ 2: フェーズ 2b 無作為化、二重盲検、プラセボ対照、用量範囲の導入サブスタディで、導入療法としてのエトラシモドを評価し、フェーズ 3 での継続評価のために導入および維持用量を選択します。サブスタディ 1 は現在参加者募集中。
サブスタディ 2 - 導入: 導入療法としてのエトラシモドを評価するための第 3 相無作為化二重盲検プラセボ対照サブスタディ。
サブスタディ 3 - 維持療法: 維持療法としてのエトラシモドを評価するための第 3 相無作為化二重盲検プラセボ対照サブスタディ。 サブスタディ 1 とサブスタディ 2 の参加者は、サブスタディ 3 に登録されます。
サブスタディ 4 - 長期延長: 少なくとも 52 週間の治療を完了した参加者のための長期延長サブスタディ。 サブスタディ 3 とサブスタディ A の参加者は、サブスタディ 4 に登録される予定です。
研究の種類
入学 (実際)
段階
- フェーズ2
- フェーズ 3
連絡先と場所
研究場所
-
-
Alabama
-
Dothan、Alabama、アメリカ、36301
- Digestive Health Specialists
-
Dothan、Alabama、アメリカ、36301
- Dothan Eyecare-Dr. Brent McKinley (OCT Location)
-
Dothan、Alabama、アメリカ、36301
- Center for Digestive Health (Endoscopy Location)
-
Dothan、Alabama、アメリカ、36301
- Pulmonary Associates (PFT Location)
-
Dothan、Alabama、アメリカ、36305
- Flowers Hospital (Imaging Location)
-
Mobile、Alabama、アメリカ、36608
- Digestive Health Specialists (Satellite Clinic Location)
-
Mobile、Alabama、アメリカ、36608
- Premier Medical Group East (Opthalmology & Optometry Facility)
-
Mobile、Alabama、アメリカ、36608
- Pulmonary Associates (Chest X-Ray & PFT Facility)
-
Mobile、Alabama、アメリカ、36608
- Surgicare of Mobile (Endoscopy & Biopsy Facility)
-
-
Arizona
-
Peoria、Arizona、アメリカ、85381
- Arizona Retina Institute/ Phoenix Retina Associates(OCT)
-
Peoria、Arizona、アメリカ、85381
- SimonMed Imaging (Imaging)
-
Sun City、Arizona、アメリカ、85351
- Sun City Endoscopy Center (Endoscopy)
-
-
California
-
Apple Valley、California、アメリカ、92307
- Om Research LLC
-
Apple Valley、California、アメリカ、92307
- Victor Valley Advanced Imaging
-
La Jolla、California、アメリカ、92037
- UCSD lnvestigational Drug Service Pharmacy
-
La Jolla、California、アメリカ、92093
- Shiley Eye Institute (OCT)
-
La Jolla、California、アメリカ、92037
- Koman Family Outpatient Pavilion (ENDO)
-
La Jolla、California、アメリカ、92037
- Perlman Medical Offices
-
La Jolla、California、アメリカ、92037
- UCSD Clinical and Translational Research Institute
-
La Jolla、California、アメリカ、92037
- UCSD Health System (Endo/PFT/DLCO)
-
Lancaster、California、アメリカ、93534
- Om Research LLC
-
Lancaster、California、アメリカ、93534
- A V Pediatrics, Allergy and Family Medicine - PFT
-
Lancaster、California、アメリカ、93534
- Advanced Endoscopy and Pain Center - Colonoscopy
-
Lancaster、California、アメリカ、93534
- Advanced Imaging Center - Chest X-Ray
-
Lancaster、California、アメリカ、93534
- Antelope Valley Eye Care - Ophthalmologist
-
Lancaster、California、アメリカ、93534
- AV Pediatrics Allergy and Family Medicine
-
Lancaster、California、アメリカ、93534
- Jatinder S. Pruthi, MD FACG CPI
-
Murrieta、California、アメリカ、92563
- United Medical Doctors
-
Victorville、California、アメリカ、92392
- Retina Consultants of Southern California
-
Victorville、California、アメリカ、92395
- Physicians Surgery Center
-
-
Colorado
-
Colorado Springs、Colorado、アメリカ、80907
- Peak Gastroenterology Associates
-
Colorado Springs、Colorado、アメリカ、80903
- Front Range Endoscopy Center
-
Colorado Springs、Colorado、アメリカ、80909
- Colorado Springs Pulmonary Consultants, PC
-
Colorado Springs、Colorado、アメリカ、80909
- The Wright Eye Center (OCT Facility)
-
Colorado Springs、Colorado、アメリカ、80919
- Colorado Springs Imaging (Ultrasound and MRE Location)
-
-
Florida
-
Boca Raton、Florida、アメリカ、33487
- Xera Med Research
-
Boynton Beach、Florida、アメリカ、33472
- RecioMed Clinical Research Network, Inc
-
Brandon、Florida、アメリカ、33511
- Florida Advanced Gastroenterology Center - Rahman Nakshabendi MD and Imad Nakshabendi, MD
-
Clearwater、Florida、アメリカ、33756
- West Coast Endoscopy Center (Endoscopy Procedures)
-
Clearwater、Florida、アメリカ、33756
- Bay Area Chest Physicians, P.A. (Pulmonary Function Test)
-
Clearwater、Florida、アメリカ、33761
- Northwood Vision (Optical Coherence Tomography)
-
Clearwater、Florida、アメリカ、33761
- Safety Harbor Surgery (Endoscopy Procedures)
-
Clearwater、Florida、アメリカ、33762
- Gastro Florida (Regulatory Administrative Duties)
-
Coral Gables、Florida、アメリカ、33134
- Beraja Medical Institute (OCT)
-
Hialeah、Florida、アメリカ、33012
- Advanced Eye Center
-
Jacksonville、Florida、アメリカ、32256
- Encore Borland-Groover Clinical Research
-
Jacksonville、Florida、アメリカ、32207
- UF Health Imaging Center-Emerson (chest x-rays)
-
Jacksonville、Florida、アメリカ、32207
- UF Health Laboratory Emerson (blood draws)
-
Jacksonville、Florida、アメリカ、32209
- UF Health Jacksonville Respiratory Therapy (PFT and DLCO)
-
Jacksonville、Florida、アメリカ、32209
- UF Health Jacksonville-Faculty Clinic (ileocolonoscopy and biopsy)
-
Jacksonville、Florida、アメリカ、32209
- UF Health Opthalmology - Jacksonville (Ophthalmology with OCT)
-
Jacksonville、Florida、アメリカ、32209
- UF Health Radiology-Jacksonville (chest x-rays)
-
Jacksonville、Florida、アメリカ、32216
- Cisca Pulmonary & Critical Care (PFT Facility)
-
Jacksonville、Florida、アメリカ、32216
- Nicolitz Eye Consultants (OCT Facility)
-
Jacksonville、Florida、アメリカ、32256
- Borland-Groover Clinic (Endoscopy Facility)
-
Jupiter、Florida、アメリカ、33458
- Jupiter Outpatient Surgery Center
-
Kissimmee、Florida、アメリカ、34741
- IHS Health, LLC
-
Largo、Florida、アメリカ、33773
- Lee Shettle Eye & Hearing (Ophthalmoscopy Only)
-
Miami、Florida、アメリカ、33133
- Infinite Clinical Research
-
Miami、Florida、アメリカ、33156
- Research Associates of South Florida
-
Miami、Florida、アメリカ、33176
- Anchor Medical Research, LLC
-
Miami、Florida、アメリカ、33134
- The Endoscopy Center (Endoscopy Procedure)
-
Miami、Florida、アメリカ、33173
- Juan Barrio, MD (PFT when needed)
-
Miami、Florida、アメリカ、33133
- Pulmonology Physicians of South Florida
-
Miami、Florida、アメリカ、33133
- Reina Eye Care P.A.
-
Miami、Florida、アメリカ、33155
- La Salud Research Clinic Inc.
-
Miami、Florida、アメリカ、33156
- South Florida Center for Endoscopy and Digestive Disease, LLC
-
Naples、Florida、アメリカ、34102
- Gastroenterology Group of Naples
-
Naples、Florida、アメリカ、34102
- Gulfshore Endoscopy Center
-
Naples、Florida、アメリカ、34103
- Retina Consultants of Southwest Florida OCT only
-
Naples、Florida、アメリカ、34109
- Lisette Delgado Sanchez, MD PFT only
-
Orlando、Florida、アメリカ、32825
- Pediatric & Adult Research Center
-
Palmetto Bay、Florida、アメリカ、33157
- IMIC Inc.
-
Palmetto Bay、Florida、アメリカ、33157
- IMIC Inc
-
Port Orange、Florida、アメリカ、32127
- Advanced Medical Research Center
-
Seminole、Florida、アメリカ、33777
- Bardmoor GastroEnterology
-
South Miami、Florida、アメリカ、33143
- Larkin Community Hospital (Endoscopy Procedure)
-
St. Petersburg、Florida、アメリカ、33705
- St. Petersburg Endoscopy Center (Endoscopy Procedures)
-
St. Petersburg、Florida、アメリカ、33707
- Pasadena Center for Asthma and Lung Disorders (PFT and DLCO Only)
-
St. Petersburg、Florida、アメリカ、33709
- Bay Area Endoscopy and Surgery Center (Endoscopy only)
-
St. Petersburg、Florida、アメリカ、33709
- Theia Clinical Research, LLC
-
St. Petersburg、Florida、アメリカ、33710
- Advanced Research Institute Inc.(IP and PFT)
-
Sun City Center、Florida、アメリカ、33573
- Absolute Surgical Specialist - Craig Amshel, MD
-
Tampa、Florida、アメリカ、33612
- USF Health Morsani Center for Advanced Healthcare
-
Tampa、Florida、アメリカ、33606
- USF Health South Tampa Center for Advanced Healthcare
-
Tampa、Florida、アメリカ、33609
- GCP Clinical Research,LLC
-
Tampa、Florida、アメリカ、33609
- South Tampa Surgery Center
-
Tampa、Florida、アメリカ、33609
- Newsome Eye Specialist (OCT Procedures Only)
-
Tampa、Florida、アメリカ、33606
- Lab - Processing/ Storage
-
Tampa、Florida、アメリカ、33609
- LoCicero Medical Group
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30342
- Atlanta Gastroenterology Associates
-
Atlanta、Georgia、アメリカ、30309
- Digestive Healthcare of Georgia
-
Atlanta、Georgia、アメリカ、30324
- Ross Eyecare - Opthalmoscopy and OCT
-
Atlanta、Georgia、アメリカ、30342
- Atlanta Gastroenterology Associates (endoscopy only)
-
Atlanta、Georgia、アメリカ、30342
- Atlanta Gastroenterology Associates(IP only)
-
Atlanta、Georgia、アメリカ、30309
- Peachtree Allergy and Asthma Clinic - Chest X-rays and PFTs
-
-
Illinois
-
Arlington Heights、Illinois、アメリカ、60005
- GI Alliance
-
Arlington Heights、Illinois、アメリカ、60005
- Northwest Endoscopy Center (Endoscopy)
-
Gurnee、Illinois、アメリカ、60031
- GI Alliance (PFT)
-
Gurnee、Illinois、アメリカ、60031
- Illinois Gastroenterology Group-Gurnee (Patients Seen; IP Delivered)
-
Gurnee、Illinois、アメリカ、60031
- Medical Eye Services LTD (Ophthalmoscopy with OCT)
-
Lake Bluff、Illinois、アメリカ、60044
- North Shore Endoscopy Center (Endoscopy)
-
Libertyville、Illinois、アメリカ、60048
- Libertyville Imaging Center (Diagnostic Imaging)
-
Morton Grove、Illinois、アメリカ、60053
- 3T Imaging of Morton Grove (Diagnostic Imaging)
-
-
Maryland
-
Columbia、Maryland、アメリカ、21045
- Cascades Endoscopy Center
-
Columbia、Maryland、アメリカ、21044
- Charter Radiology
-
Columbia、Maryland、アメリカ、21045
- Gastro Center of Maryland, LLC
-
Hanover、Maryland、アメリカ、21076
- Kaylani Eye Care ( Optical Coherence Tomography and Opthalmoscopy only)
-
Laurel、Maryland、アメリカ、20707
- Lung Center (Pulmonary Function Test only)
-
-
Mississippi
-
Jackson、Mississippi、アメリカ、39216
- Southern Therapy and Advanced Research, LLC
-
Jackson、Mississippi、アメリカ、39216
- A Terrell Williams, MD, PLLC (OCT)
-
Jackson、Mississippi、アメリカ、39216
- Jackson Pulmonary Associates (PFT)
-
Jackson、Mississippi、アメリカ、39216
- St. Dominic Ambulatory Surgery Center (colonoscopy, Endoscopy)
-
-
Missouri
-
Creve Coeur、Missouri、アメリカ、63141
- Barnes-Jewish West County Hospital (Additional Endoscopy Location)
-
St Louis、Missouri、アメリカ、63110
- Barnes-Jewish Hospital
-
St Louis、Missouri、アメリカ、63110
- Washington University School of Medicine
-
St Louis、Missouri、アメリカ、63108
- Washington University School of Medicine
-
-
New Jersey
-
Freehold、New Jersey、アメリカ、07728
- Allied Health Clinical Research Organization, LLC
-
Freehold、New Jersey、アメリカ、07728
- Freehold Endoscopy Associates, LLC d/b/a Endoscopy Center of Monmouth County
-
Freehold、New Jersey、アメリカ、07728
- Freehold Ophthalmology
-
Freehold、New Jersey、アメリカ、07728
- Monmouth Ocean Pulmonary Medicine
-
Freehold、New Jersey、アメリカ、07728
- Princeton Radiology
-
-
New York
-
New York、New York、アメリカ、10016
- NYU Langone Health
-
New York、New York、アメリカ、10016
- NYU Langone Inflammatory Bowel Disease Center
-
New York、New York、アメリカ、10016
- NYU Langone Eye Center (Ophthalmology)
-
New York、New York、アメリカ、10016
- NYU Langone Health - Ambulatory Care Center
-
New York、New York、アメリカ、10016
- NYU Langone Health, Investigational Pharmacy, Perlmutter Cancer Center
-
New York、New York、アメリカ、10016
- NYU Pulmonary and Critical Care Associates (Pulmonary)
-
-
North Carolina
-
Charlotte、North Carolina、アメリカ、28215
- Carolinas Research Center
-
Charlotte、North Carolina、アメリカ、28204
- Queen City Gastroenterology and Hepatology (Endoscopy)
-
Charlotte、North Carolina、アメリカ、28211
- Greenman Eye Associates (OCT)
-
Charlotte、North Carolina、アメリカ、28273
- Cornerstone Medical (Imaging & PFT)
-
-
Ohio
-
Chardon、Ohio、アメリカ、44024
- Geauga Sleep Center(PFT only)
-
Cincinnati、Ohio、アメリカ、45219
- UC Health Physicians Office
-
Cincinnati、Ohio、アメリカ、45229
- UC Health (Pulmonary Function Testing)
-
Cincinnati、Ohio、アメリカ、45219
- UC Health Hoxworth (OCT only)
-
Cincinnati、Ohio、アメリカ、45219
- University of Cincinnati Medical Center (PFT and Endoscopy location)
-
Mentor、Ohio、アメリカ、44060
- Great Lakes Gastroenterology Research, LLC
-
Mentor、Ohio、アメリカ、44060
- The Endoscopy Center of Lake County
-
Mentor、Ohio、アメリカ、44060
- Ophthalmic Physicians Incorporated (OCT Only)
-
Mentor、Ohio、アメリカ、44060
- Vitreo Retinal Consultants(OCT only)
-
Willoughby、Ohio、アメリカ、44094
- Lake Pulmonary Associates (PFT only)
-
Willoughby Hills、Ohio、アメリカ、44094
- Retina Specialists of Ohio(OCT only)
-
-
Oklahoma
-
Norman、Oklahoma、アメリカ、73071
- Norman Endoscopy Center
-
Norman、Oklahoma、アメリカ、73071
- Physicians and Surgeons X-Ray
-
Oklahoma City、Oklahoma、アメリカ、73118
- Central Sooner Research
-
Oklahoma City、Oklahoma、アメリカ、73102
- Hightower Clinical
-
Oklahoma City、Oklahoma、アメリカ、73102
- Saint Anthony Endoscopy Center
-
Oklahoma City、Oklahoma、アメリカ、73102
- SSM Health, Saint Anthony Hospital
-
Oklahoma City、Oklahoma、アメリカ、73120
- Johnston Opthalmology
-
-
Pennsylvania
-
Hershey、Pennsylvania、アメリカ、17033
- Penn State Milton S. Hershey Medical Center
-
-
Texas
-
Austin、Texas、アメリカ、78705
- Central Texas Clinical Research
-
Cypress、Texas、アメリカ、77429
- Houston Pulmonary Sleep and Allergy Associates (PFT)
-
Houston、Texas、アメリカ、77030
- The University of Texas Health Science Center at Houston
-
Houston、Texas、アメリカ、77030
- Baylor St. Luke's Medical Center
-
Houston、Texas、アメリカ、77047
- Pearland Surgery Center
-
Houston、Texas、アメリカ、77030
- Alkek Eye Center Jamail Specialty Care Center (OCT)
-
Houston、Texas、アメリカ、77024
- Houston Eye Associates (For Eye Examination)
-
Houston、Texas、アメリカ、77030
- Baylor College of Medicine - Baylor St. Luke's Medical Center
-
Houston、Texas、アメリカ、77030
- Baylor St. Luke's Medical Center - McNair Campus (pharmacy)
-
Houston、Texas、アメリカ、77030
- Baylor St. Luke's Medical Center - McNair Campus
-
Houston、Texas、アメリカ、77030
- Baylor St. Luke's Medical Center Endoscopy - McNair Campus
-
Houston、Texas、アメリカ、77030
- Mann Eye Institute
-
Houston、Texas、アメリカ、77030
- Memorial Hermann Hospital- TMC Investigational Drugs Services Pharmacy (Drug Storage)
-
Houston、Texas、アメリカ、77034
- Bay Area Endoscopy Center, LLC
-
Houston、Texas、アメリカ、77055
- Memorial Endoscopy Center (For Colonoscopy)
-
Houston、Texas、アメリカ、77065
- Eye Specialists of Texas
-
Houston、Texas、アメリカ、77065
- Northside Gastroenterology Associates PA
-
Houston、Texas、アメリカ、77079
- Memorial Pulmonology(For PFT)
-
Houston、Texas、アメリカ、77204
- Digestive Health Associates
-
Houston、Texas、アメリカ、77204
- Memorial Hermann Memorial City Digestive Health Center (For Colonoscopy)
-
Pearland、Texas、アメリカ、77584
- LinQ Research, LLC
-
Tyler、Texas、アメリカ、75701
- Tyler Research Institute, LLC
-
Tyler、Texas、アメリカ、75701
- UT Health East Texas Physicians (pulmonary functions only)
-
Tyler、Texas、アメリカ、75701
- Christus Trinity Mother Frances Endoscopy Center (endoscopies only)
-
Tyler、Texas、アメリカ、75701
- Heaton Eye Associates (OCT only)
-
Victoria、Texas、アメリカ、77904
- Victoria Gastroenterology
-
Victoria、Texas、アメリカ、77904
- Citizens Healthplex (for PFT only)
-
Victoria、Texas、アメリカ、77904
- Surgery Center (For endoscopy only)
-
Victoria、Texas、アメリカ、77904
- Victoria Eye Center (For OCT only)
-
Webster、Texas、アメリカ、77598
- GI Alliance Webster
-
-
Virginia
-
Forest、Virginia、アメリカ、24551
- Harman Eye Center (OCT only)
-
Lynchburg、Virginia、アメリカ、24502
- Blue Ridge Medical Research
-
Lynchburg、Virginia、アメリカ、24501
- Lynchburg Pulmonary Associates, Inc. (PFT only)
-
-
Washington
-
Issaquah、Washington、アメリカ、98029
- Swedish Endoscopy Center - Issaquah
-
Seattle、Washington、アメリカ、98122
- Swedish Medical Center
-
Seattle、Washington、アメリカ、98104
- Swedish Gastroenterology
-
Seattle、Washington、アメリカ、98104
- Pacific Northwest Retina
-
Seattle、Washington、アメリカ、98104
- Richard Bensinger, MD
-
Seattle、Washington、アメリカ、98122
- First Hill Endoscopy Center
-
Seattle、Washington、アメリカ、98122
- Pulmonary Function Lab
-
-
Wisconsin
-
Milwaukee、Wisconsin、アメリカ、53226
- Froedtert Memorial Lutheran Hospital
-
-
-
-
Prov. de Buenos Aires
-
Ciudadela、Prov. de Buenos Aires、アルゼンチン、1702
- Instituto Medico Elsa Perez(I.M.E.P)
-
Ciudadela、Prov. de Buenos Aires、アルゼンチン、B1702GIK
- Instituto Medico Elsa Perez (I.M.E.P.) (Local Lab)
-
Ciudadela、Prov. de Buenos Aires、アルゼンチン、B1702GIK
- Instituto Medico Elsa Perez (I.M.E.P.) (Pharmacy)
-
Hurlingham、Prov. de Buenos Aires、アルゼンチン、B1686NCI
- Estudio de La Vision (OCT, Ophthalmoscopy)
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、アルゼンチン、S2000DEJ
- Instituto Medico de la Fundacion Estudios Clinicos
-
Rosario、Santa Fe Province、アルゼンチン、S2000AUC
- Gastroenterologia Rosario (Endoscopy)
-
Rosario、Santa Fe Province、アルゼンチン、S2000CTC
- Microcirugia Ocular SA (OCT, Ophthalmoscopy)
-
Rosario、Santa Fe Province、アルゼンチン、S2000KZD
- Consultorios extemos de Sanatorio Parque (PFT with DLCO, Pulmonar Functional Test with DLCO)
-
-
Tucumán Province
-
San Miguel de Tucumán、Tucumán Province、アルゼンチン、T4000AXL
- Centro de Investigaciones Médicas Tucuman
-
-
-
-
-
Liverpool、イギリス、L7 8XP
- Royal Liverpool University Hospital
-
London、イギリス、SE1 9RT
- Guys & St Thomas Hospital
-
Norwich、イギリス、NR4 7UQ
- Quadram Institute Clinical Research Facility
-
-
-
-
-
Afula、イスラエル、1834111
- Haemek Medical Center
-
Jerusalem、イスラエル、9103102
- Shaare Zedek Medical Center
-
Ramat Gan、イスラエル、5262000
- Chaim Sheba Medical Center
-
Tel Aviv、イスラエル、6423906
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Catania、イタリア、829-95126
- Azienda Ospedaliera Ospedale Cannizzaro
-
Catanzaro、イタリア、88100
- A.O. Mater Domini, U.O. Fisiopatologia Apparato Digerente Campus Universitario "Salvatore Venuta"
-
Catanzaro、イタリア、88100
- A.O. Mater Domini, U.O. Fisiopatologia Apparato Digerente
-
Catanzaro、イタリア、88100
- CAMPUS GERMANETO Magazzino farmaci e dispositivi medici, uffici
-
Pavia、イタリア、27100
- Fondazione IRCCS Policlinico San Matteo - Centro per lo Studio e la Cura delle Amiloidosi Sistemiche
-
Rome、イタリア、00189
- PFT address: Azienda Ospedaliero-Universitaria Sant' Andrea UOC Pneumologia
-
Verona、イタリア、37024
- IRCCS Ospedale Sacro Cuore Don Calabria
-
Verona、イタリア、37134
- OCT/PFT/Endoscopy address: CRC - Cenro Ricerche Cliniche di Verona
-
-
Foggia
-
San Giovanni Rotondo、Foggia、イタリア、71013
- IRCCS Ospedale Casa Sollievo della Sofferenza
-
San Giovanni Rotondo、Foggia、イタリア、71013
- OCT/ PFT/ Endoscopy address: IRCCS Ospedale Casa Sollievo della Sofferenza
-
-
MI
-
Milan、MI、イタリア、20132
- Ospedale San Raffaele
-
-
Milan
-
Garbagnate Milanese、Milan、イタリア、20024
- ASST Rhodense - Pneumology Unit
-
Milan、Milan、イタリア、20017 Rho
- ASST Rhodense, U.O.C. Gastroenterologia ed Endoscopia Digestiva
-
Rho、Milan、イタリア、20017
- ASST Rhodense - Ophthalmology Unit
-
-
Milano
-
Rozzano、Milano、イタリア、20089
- Irccs Humanitas Research Hospital
-
-
Verona
-
Negrar、Verona、イタリア、37024
- OCT/ PFT/ Endoscopy address: IRCCS Ospedale Sacro Cuore Don Calabria
-
-
-
-
-
Kochi、インド、682027
- Aster Medcity, Aster DM Healthcare Ltd.
-
-
Gujarat
-
Surat、Gujarat、インド、395002
- Surat Institute of Digestive Sciences
-
-
Haryana
-
Gurugram、Haryana、インド、122002
- Fortis Memorial Research Institute
-
-
Maharashtra
-
Nagpur、Maharashtra、インド、440010
- Midas Multispeciality Hospital Pvt. Ltd
-
-
Rajasthan
-
Jaipur、Rajasthan、インド、302001
- S. R. Kalla Memorial Gastro & General Hospital
-
-
-
-
-
Kharkiv、ウクライナ、61124
- Communal Non-commercial Enterprise City Clinical Hospital #13 of Kharkiv City Council
-
Kharkiv、ウクライナ、61024
- LLC "EyeQClinic"
-
Kharkiv、ウクライナ、61022
- Llc "Ldts Skaymed'
-
Kharkiv、ウクライナ、61037
- Communal Non-commercial Enterprise Prof. O.O. Shalimov City Clinical Hospital #2 of Kharkiv
-
Kharkiv、ウクライナ、61045
- Llc "Medical Center Oftalmika"
-
Kharkiv、ウクライナ、61103
- Municipal Health Care "Kharkiv City Hospital Ambulance and Emergency Medical care
-
Kyiv、ウクライナ、01135
- Medical Center of Limited Liability Company Harmoniia Krasy
-
Kyiv、ウクライナ、02091
- Med Center 'Ok!Clinic+' of Comp with limited liability "Int Inst of Clin Research", Unit of Gastro
-
Kyiv、ウクライナ、04210
- Private Enterprise "Clinic Medicom"
-
Lutsk、ウクライナ、43005
- CE Volyn Reg Clinical Hospital ofVolyn Reg Council, Surgical (Endocrine and Abdominal Pathology)
-
Vinnytsia、ウクライナ、21000
- Private Enterprise Diagnostic Center "Mediscan"
-
Vinnytsia、ウクライナ、21009
- Medical Center of LLC Health Clinic, Medical Clinical Research Center, Unit of Gastroenterology,
-
Vinnytsia、ウクライナ、21018
- CNE of M.I. Pyrohov Vinnytsia Regional Clinical Hospital of Vinnytsia Regional Council, Reg
-
Vinnytsia、ウクライナ、21029
- Scientific and Research Institute of Invalid Rehabilitation (Educational, Scientific and Treatment
-
-
-
-
-
Alexandria、エジプト、21131
- Alexandria Clinical Research Center , Faculty of Medicine , Alexandria University
-
Cairo、エジプト
- National Hepatology and Tropical Medicine Research Institute
-
Cairo、エジプト、11556
- Ain Shams University Hospital
-
Cairo、エジプト
- Air Force Specialized Hospital(AFSH)
-
Cairo、エジプト
- Cairo University , Kasr Al Aini Hospital
-
Dakahlia、エジプト
- Egyptian Liver Research Institute and Hospital ( ELRIAH)
-
Giza、エジプト
- Theodor Bilharz Research Institute Research Ethics Committee
-
Menofeya、エジプト、32511
- National Liver Institute
-
-
-
-
-
Amsterdam、オランダ、1105 AZ
- Academic Medical Centre
-
Utrecht、オランダ、3584 CX
- UMC Utrecht
-
-
-
-
New South Wales
-
Macquarie University、New South Wales、オーストラリア、2109
- Macquarie University Hospital
-
Macquarie University、New South Wales、オーストラリア、2109
- Macquarie University Hospital Pharmacy
-
Macquarie University、New South Wales、オーストラリア、2109
- Macquarie Respiratory Services
-
Macquarie University、New South Wales、オーストラリア、2109
- Macquarie University Hospital Clinical Trials
-
Macquarie University、New South Wales、オーストラリア、2109
- MQ Health Ophthalmology
-
-
Queensland
-
Brisbane、Queensland、オーストラリア、4029
- Royal Brisbane & Women's Hospital
-
North Mackay、Queensland、オーストラリア、4740
- Coral Sea Clinical Research Institute
-
-
Victoria
-
Bellfield、Victoria、オーストラリア、3081
- MCES Practice Pty Ltd operating as Comprehensive Eye Surgeons
-
Epping、Victoria、オーストラリア、3076
- The Northern Hospital
-
Heidelberg、Victoria、オーストラリア、3084
- Austin Hospital
-
Melbourne、Victoria、オーストラリア、3011
- Vision Eye Institute
-
Melbourne、Victoria、オーストラリア、3011
- Footscray Hospital
-
Parkville、Victoria、オーストラリア、3050
- The Royal Melbourne Hospital
-
Rosanna、Victoria、オーストラリア、3084
- Heidelberg Eye Clinic
-
-
Western Australia
-
Murdoch、Western Australia、オーストラリア、6150
- Fiona Stanley Hospital
-
Nedlands、Western Australia、オーストラリア、6009
- Lions Eye Institute Limited
-
O'Connor、Western Australia、オーストラリア、6163
- The trustee for The RTS Unit Trust trading as Respiratory Testing Services
-
-
-
-
-
Graz、オーストリア、8036
- LKH Universitats-Klinikum Graz
-
Innsbruck、オーストリア、A-6020
- Medical University Innsbruck, Internal Medicine Ⅰ
-
Vienna、オーストリア、1090
- AKH Wien- Universitatsklinik fiir Innere Medizin III
-
Vienna、オーストリア、1090
- Univ.-Professor Dr. Mehrdad Baghestanian
-
Vienna、オーストリア、1090
- AKH Wien- Universitatsklinik fur Innere Medizin III
-
-
-
-
Quebec
-
Montreal、Quebec、カナダ、H3G 1A4
- McGill University Health Centre - Montreal General Hospital (Electrocardiogram Clinic)
-
Montreal、Quebec、カナダ、H3G 1A4
- McGill University Health Centre - Montreal General Hospital (Endoscopy Clinic)
-
Montreal、Quebec、カナダ、H3G 1A4
- McGill University Health Centre - Montreal General Hospital (Pharmacy)
-
Montreal、Quebec、カナダ、H3G 1A4
- McGill University Health Centre - Montreal General Hospital (Radiology)
-
Montreal、Quebec、カナダ、H3G 1A4
- McGill University Health Centre - Montreal General Hospital (Research Site)
-
Montreal、Quebec、カナダ、H4A 3J1
- Centre for Innovative Medicine - Research Institute of the McGill University Health Centre(Pulmonary
-
Montreal、Quebec、カナダ、H4P 2S4
- Eye Health MD (Ophthalmology)
-
-
-
-
-
Alexandroupoli、ギリシャ、681 00
- University General Hospital of Alexandroupoli
-
Athens、ギリシャ、10676
- General Hospital of Athens "Evangelismos"
-
-
Crete
-
Heraklion、Crete、ギリシャ、71500
- Univerisity General Hospital of Heraklion
-
-
-
-
-
Zagreb、クロアチア、10000
- University Hospital Center Zagreb
-
-
-
-
-
Tbilisi、グルジア、0160
- LTD Aversi Clinic
-
Tbilisi、グルジア、0159
- LTD Institute of Clinical Cardiology
-
Tbilisi、グルジア、0160
- JSC Infectious Diseases, AIDS and Clinical Immunology Research Center
-
Tbilisi、グルジア、0160
- LTD Academician Nikoloz Kipshidze Central University Clinic
-
Tbilisi、グルジア、0172
- Malkhaz Katsiashvili Multiprofile Emergency Medicine Center, LTD
-
Tbilisi、グルジア、0179
- LTD Medical Center "CITO"
-
-
-
-
Quindío Department
-
Armenia、Quindío Department、コロンビア、630004
- IPS Fundacion Cardiomet CEQUIN
-
-
Valle del Cauca Department
-
Cali、Valle del Cauca Department、コロンビア、760035
- Centro de lnvestigaciones Clinicas S.A.S
-
-
-
-
-
Bern、スイス、3010
- Inselspital Bern
-
Bern、スイス、3012
- OCT/Ophtalmoscopy: Berner Augenklinik am Lindenhofspital
-
-
-
-
-
Las Palmas de Gran Canaria、スペイン、35010
- Hospital Universitario de Gran Canaria Dr. Negrín
-
Madrid、スペイン、28046
- Hospital Universitario La Paz
-
-
Ciudad REAL
-
Tomellso、Ciudad REAL、スペイン、13700
- Hospital General de Tomelloso
-
-
-
-
-
Banská Bystrica、スロバキア、975 17
- Fakultna nemocnica s poliklinikou F.D.Roosevelta
-
Bardejov、スロバキア、08501
- ALIAN. s.r.o .. Ambulancia vnutorneho lekarstva
-
Košice、スロバキア、040 13
- ENDOMED, s.r.o. Gastroenterologicka ambulancia
-
Lipany、スロバキア、082 71
- Opthalmology outpatient clinic, MUDr. Michal Popovec, s.r.o.
-
Nitra、スロバキア、949 01
- KM Management spol.s.r.o. Gastroenterologicke a hepatologicke centrum
-
Prešov、スロバキア、080 01
- GASTRO LM s.r.o., Gastroenterologicka ambulancia
-
Prešov、スロバキア、080 01
- Pneumology: PULMO, s.r.o.
-
-
-
-
-
Belgrade、セルビア、11000
- Clinical Center Zvezdara
-
-
-
-
-
Horažďovice、チェコ、341 01
- MUDr. Jaroslava Skalova
-
Hradec Králové、チェコ、500 12
- Hepato-gastroenterologie HK, s.r.o.
-
Hradec Králové、チェコ、500 12
- VISUS, spol s.r.o.
-
Klatovy、チェコ、339 01
- GASTRO JeKa, s.r.o.
-
Klatovy、チェコ、339 01
- Klatovska nemocnice a.s.
-
Olomouc、チェコ、779 00
- PreventaMed s.r.o.
-
Olomouc、チェコ、779 00
- Ocni ordinace Olomouc
-
Olomouc、チェコ、779 00
- MUDr. Pavlina Kazinotova s.r.o.
-
-
-
-
RM
-
Santiago、RM、チリ、8330034
- Centro de Investigaciones Clinicas de la Universidad Catolica
-
-
Santiago Metropolitan
-
Santiago、Santiago Metropolitan、チリ、7620157
- Clinica Universidad de Los Andes
-
Santiago、Santiago Metropolitan、チリ、8330336
- CeCim Biocinetic
-
-
-
-
-
Aalborg、デンマーク、9000
- Aalborg University Hospital, Department of Medical Gastroenterology, Medicinerhuset
-
Hvidovre、デンマーク、2650
- Hvidovre University Hospital
-
-
-
-
-
Ankara、トルコ(Türkiye)、06500
- Gazi University Medical Faculty
-
Ankara、トルコ(Türkiye)、06100
- Hacettepe University Medical Faculty
-
Ankara、トルコ(Türkiye)、06800
- T.C. Saglik Bakanligi Ankara Sehir Hastanesi
-
Antalya、トルコ(Türkiye)、07100
- Saglik Bilimleri Universitesi Antalya Egitim ve Arastirma Hastanesi
-
Izmir、トルコ(Türkiye)、35100
- Ege Universitesi Tip Fakultesi Hastanesi
-
Kocaeli、トルコ(Türkiye)、41380
- Kocaeli University Research and Training Hospital
-
Yenişehir、トルコ(Türkiye)、33343
- Mersin University Faculty of Medicine
-
-
-
-
-
Augsburg、ドイツ、86156
- Universitaetsklinikum Augsburg
-
Brandenburg an der Havel、ドイツ、14770
- Staedtisches Klinikum Brandenburg
-
Frankfurt、ドイツ、60431
- Prof. Dr. med. Dr. med. Habil. Jens Buhren, FEBO
-
Frankfurt am Main、ドイツ、60431
- Agaplesion Markus Krankenhaus
-
Hamburg、ドイツ、20251
- HaFCED e.K. - Hamburgisches Forschungsinstitut für chronisch entzündliche Darmerkrankungen
-
Jena、ドイツ、07747
- Universitaetsklinikum Jena
-
Jena、ドイツ、07747
- OCT/Ophtalmoscopy address: Universitaetsklinikum Jena
-
Jena、ドイツ、07747
- PFT address: Universitaetsklinikum Jena
-
Kassel、ドイツ、34121
- PFT address: Praxis fur Pneumologie und Allergologie
-
Kassel、ドイツ、34177
- OCT/Ophtalmoscopy address: Augenarztpraxis Dr. Karola Hassan
-
Kiel、ドイツ、24105
- Nordblick Augenklinik
-
Kiel、ドイツ、24105
- Universitatsklinikum Schleswig-Holstein- Campus Kiel
-
Nürtingen、ドイツ、72622
- Dr. Irina Hasewinkel
-
Nürtingen、ドイツ、72622
- Medius Klinik Nuertingen
-
-
Hassen
-
Kassel、Hassen、ドイツ、34117
- Gastroenterologie Opernstraβe
-
-
-
-
-
Budapest、ハンガリー、1136
- Pannonia Maganorvosi Centrum
-
Budapest、ハンガリー、1033
- Clinexpert Egeszsegugyi Szolgaltato es Kereskedelmi Kft. (abbreviated name: Clinexpert Kft.)
-
Budapest、ハンガリー、1062
- Ophthalmology procedures: Magyar Honvedseg Egeszsegugyi Kozpont
-
Budapest、ハンガリー、1062
- Pulmonary procedures: Vasutegeszsegugyi Nonprofit Kozhasznu K ft.
-
Budapest、ハンガリー、1134
- Ophthalmology, OCT: Medicover Zrt.
-
Budapest、ハンガリー、1139
- Chest X-ray: XIII. keruleti Egeszsegugyi Szolgalat Kozhasznu Nonprofit Kft.
-
Békéscsaba、ハンガリー、5600
- Bekes Megyei Kozponti Korhaz Dr. Rethy Pal Tagkorhaz, 4. Belgyogyaszat es 2. Gasztroenterologia
-
-
Heves County
-
Gyöngyös、Heves County、ハンガリー、3200
- Bugat Pal Korhaz, Gasztroenterologia
-
-
Komárom-Esztergom
-
Tatabánya、Komárom-Esztergom、ハンガリー、2800
- Szent Borbala Korhaz
-
Tatabánya、Komárom-Esztergom、ハンガリー、2800
- DLCO and ophthalmology tests: Szent Borbala Korhaz
-
-
-
-
-
Amiens、フランス、80054
- CHU Amiens Picardie
-
Clermont-Ferrand、フランス、63000
- Chu Gabriel Montpied
-
Clermont-Ferrand、フランス、63000
- CHU De Clermont Ferrand - Hopital Estaing
-
Grenoble、フランス、38043
- CHU Grenoble Alpes - Hopital Michallon
-
Grenoble、フランス、38043
- Endoscopy: CHU Grenoble Alpes- Hopital Michallon
-
La Roche-sur-Yon、フランス、85925
- CHD Vendee, Unite de Recherche Clinique
-
Lille、フランス、59037
- CHU de Lille - Hôpital Claude Huriez
-
Lille、フランス、59037
- Optical Coherence Tomography and Ophthalmology CHU de Lille Hopital Roger Salengro
-
Lille、フランス、59037
- Pulmonary Function Test CHU Lille, Institut Coeur Poumon
-
Montpellier、フランス、34295
- CHU Saint-Eloi
-
Montpellier、フランス、34295
- Hopital Saint-Eloi - Pole Digestif - Hgea Recherche Clinique - Rdc
-
Nice、フランス、06202
- CHU de Nice, Hopital 1'Archet 2
-
Reims、フランス、51100
- Hopital Maison Blanche, CHU DE REIMS
-
Reims、フランス、51092
- Hopital Robert Debre
-
Reims、フランス、51100
- Hopital Robert Debre CHU DE REIMS
-
Saint-Etienne、フランス、42055
- CHU Saint Etienne - Hôpital Nord
-
Saint-Priest-en-Jarez、フランス、42270
- Optical Coherence Tomography and Ophthalmology
-
Saint-Priest-en-Jarez、フランス、42270
- Pulmonary Function Test
-
Toulouse、フランス、31059
- Hopital Rangueil
-
Toulouse、フランス、31300
- Hopital Purpan PPR pole cephalique
-
Vandœuvre-lès-Nancy、フランス、54511
- CHRU Nancy Brabois
-
-
-
-
-
Sofia、ブルガリア、1527
- UMHAT "Tsaritsa Yoanna-ISUL" EAD
-
Sofia、ブルガリア、1431
- "DCC Alexandrovska", EOOD
-
Sofia、ブルガリア、1606
- ,,University multiprofile hospital for active treatment and emergency medicine N.I. Pirogov" EAD
-
-
-
-
-
Homyel、ベラルーシ、246029
- Institution "Gomel Regional Clinical Hospital"
-
Minsk、ベラルーシ、220096
- Health care Institution "10th City Clinical Hospital"
-
Mogilev、ベラルーシ、212018
- Health Care Institution "Mogilev Hospital #1"
-
Vitebsk、ベラルーシ、210037
- Health Care Institution "Vitebsk Regional Clinical Hospital"
-
Vitebsk、ベラルーシ、210604
- Healthcare Institution "Vitebsk Regional Clinical Specialized Center"
-
-
-
-
-
Ghent、ベルギー、9000
- Universitair Ziekenhuis Gent
-
Ghent、ベルギー、9000
- AZ Maria-Middelares
-
Leuven、ベルギー、3000
- Universitaire Ziekenhuizen Leuven
-
Roeselare、ベルギー、8800
- Campus Brugsesteenweg
-
Roeselare、ベルギー、8800
- Campus Rumbeke
-
Torhout、ベルギー、8820
- Campus Rembert Torhout
-
Yvoir、ベルギー、5530
- Centre Hospitalier Universitaire UCL Namur - Site Godinne
-
-
-
-
-
Bystra、ポーランド、43-360
- Centrum Pulmonologii i Torakochirurgii w Bystrej (DLCO)
-
Karkow、ポーランド、31-156
- Specjalistyczne Gabinety Lekarskie LANDA
-
Krakow、ポーランド、30-033
- Centre De La Vision Centrum Okulistyczne(OCT, Ophthalmoscopy)
-
Krakow、ポーランド、30-307
- Medicina (Endoscopy)
-
Krakow、ポーランド、31-153
- Centrum Medyczne EVITA(Endoscopy)
-
Lodz、ポーランド、90-752
- IP Clinic Sp. z o.o.
-
Lodz、ポーランド、90-338
- Centrum Medyczne "Ksiezy Mlyn" (OCT, Ophtalmoscopy)
-
Lodz、ポーランド、93-513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatolog i im. M. Kopernika w Lodzi
-
Lodz、ポーランド、90-338
- (Centrum Medyczne Ksiezy Mlyn (OCT and Ophthalmoscopy)
-
Lodz、ポーランド、90-644
- AMICARE Sp. z o.o. sp.k
-
Lodz、ポーランド、91-053
- Centra Medyczne Medyceusz (DLCO)
-
Lodz、ポーランド、92-551
- Salve Health Care Sp. o.o., (PFT and Endoscopy)
-
Nowy Targ、ポーランド、34-400
- Allmedica Badania Kliniczne Sp. z o.o. Sp. k.
-
Oświęcim、ポーランド、32-600
- Medicome Sp. Z O.O
-
Piotrkow Trybunalski、ポーランド、97-300
- Przychodnia Okulistyczna "Oculus" Barbara Cybulska (OCT, Ophtalmoscopy)
-
Piotrkow Trybunalski、ポーランド、97-300
- Samodzielny Szpital Wojewodzki im. Mikolaja Kopernika (Endoscopy)
-
Piotrokow Trybunalski、ポーランド、97-300
- Trialmed CRS
-
Poznan、ポーランド、60-529
- Solurmed Centrum Medyczne
-
Poznan、ポーランド、60-538
- OCU Service Mikolaj Meller Sp.j.(OCT, Ophtalmoscopy)
-
Rzeszów、ポーランド、35-326
- Centrum Medyczne Medyk
-
Rzeszów、ポーランド、35-055
- Kliniczny Szpital Wojewodzki Nr 1 im. Fryderyka Chopina w Rzeszowie (Ophthalmpscopy)
-
Rzeszów、ポーランド、35-241
- Podkarpackie Centrum Chorob Plue w Rzeszowie (DLCO)
-
Strzegom、ポーランド、58-150
- Strzegomskie Centrum Medyczno - Diagnostyczne Sp. z o.o. (Endoscopy)
-
Swidnica、ポーランド、58-100
- DC-MED
-
Swidnica、ポーランド、58-100
- Centrum Medyczne EZ-MEDICA (OCT, Ophtalmoscopy)
-
Swidnica、ポーランド、58-100
- Szpital "Latawiec" -Poradnia Gruzlicy i Chorob Pluc (PFT)
-
Warsaw、ポーランド、00-635
- Centrum Zdrowia MDM
-
Warsaw、ポーランド、00-631
- Centrum Zdrowia MDM (OCT,opthalmoscopy)
-
Warsaw、ポーランド、01-138
- Instytut Gruzlicy i Chorob Pluc(DLCO)
-
Warsaw、ポーランド、02-653
- Endoterapia PFG (Endoscopy)
-
Warsaw、ポーランド、02-653
- Instytut Oka (OCT, Ophtalmoscopy)
-
Warsaw、ポーランド、03-712
- Specjalistyczne Gabinety Lekarskie Body Clinic
-
Warsaw、ポーランド、03-731
- Centrum Okulistyczne JASKRA (OCT, Ophthalmoscopy)
-
Warsaw、ポーランド、04-141
- Wojskowy lnstytut Medyczny (PFT)
-
Wroclaw、ポーランド、60-681
- EuroMediCare Szpital Specjalistyczny z Przychodniit (Endoscopy)
-
-
Greater Poland Voivodeship
-
Poznan、Greater Poland Voivodeship、ポーランド、60-681
- NSZOZ Termedica
-
-
-
-
-
Kuala Lumpur、マレーシア、59100
- University Malaya Medical Centre
-
-
-
-
-
Chihuahua City、メキシコ、31203
- Scientia Investigacion Clinica S.C.
-
Chihuahua City、メキシコ、31020
- Sanatorio Palmore A.C.
-
Chihuahua City、メキシコ、31203
- Vista Lasser de Chihuahua S.C.
-
Chihuahua City、メキシコ、31283
- Servicios Hospitalarios de México, S.A. de C.V.
-
Veracruz、メキシコ、91900
- FAICIC S. de R.L. de C.V.
-
Veracruz、メキシコ、91910
- Gabinete de Diagnostico COVADONGA
-
Veracruz、メキシコ、91918
- Alberto Collado Solorzano (Clinica Vision)
-
-
Jalisco
-
Guadalajara、Jalisco、メキシコ、44130
- Centro de Investigacion Medico Biologica Y Terapia Avanzada S.C.
-
Guadalajara、Jalisco、メキシコ、44600
- Global Glaucoma Institute
-
Guadalajara、Jalisco、メキシコ、44600
- Video Endoscopia Americas
-
Guadalajara、Jalisco、メキシコ、44670
- Comercializadora Winco S.A. de C.V.
-
-
Veracruz
-
Boca del Rio、Veracruz、メキシコ、94299
- Cirugia y Gastro de Veracruz S.A. de C.V. (Progastro)
-
-
-
-
-
Chisinau、モルドバ、2005
- "Sf. Arhanghel Mihail" Municipal Clinical Hospital, Department of Gastroenterology
-
Chisinau、モルドバ、MD2025
- PMSI Republican Clinical Hospital "Timofei Mosneaga", Department of Colorectal Surgery
-
Chisinau、モルドバ、MD2025
- PMSI Republican Clinical Hospital "Timofei Mosneaga", Department of Gastroenterology
-
Chisinau、モルドバ、MD2025
- PMSI Republican Clinical Hospital "Timofei Mosneaga", Outpatient Department
-
-
-
-
-
Vilnius、リトアニア、LT-08661
- Vilnius University Hospital Santaros Klinikos
-
-
-
-
-
Bucharest、ルーマニア、012015
- SC Centrul Medical Medicum SRL, Specialitatea Gastroenterologie
-
Bucharest、ルーマニア、022328
- Institutul Clinic Fundeni, Centrul de Gastroenterologie si Hepatologie
-
-
JUD. CLUJ
-
Cluj-Napoca、JUD. CLUJ、ルーマニア、400006
- Spitalul Clinic Judetean de Urgenta Cluj Napoca
-
-
Jud.constanta
-
Constanța、Jud.constanta、ルーマニア、900591
- Centrul de Diagnostic si Tratament Affidea, Specialitatea Medicina Interna
-
-
-
-
-
Beirut、レバノン、166830
- Hotel Dieu de France Hospital
-
Beirut、レバノン、1100 2807
- Saint George University Hospital Medical Center
-
Beirut、レバノン、113-6044
- Rafik Hariri University Hospital
-
Saida、レバノン
- Hammoud Hospital University Medical Center
-
Tripoli、レバノン
- Nini Hospital s.a:l
-
-
-
-
-
Kemerovo、ロシア、650066
- SAIH "Kemerovo Regional Clinical Hospital"
-
Novosibirsk、ロシア、630005
- LLC "SibNovoMed"
-
Novosibirsk、ロシア、630007
- Gastrocenter
-
Novosibirsk、ロシア、630007
- LLC "Novosibirskiy Gastrocentr''
-
Novosibirsk、ロシア、630084
- Hospital #12
-
Novosibirsk、ロシア、630091
- LLC "Siberian Center for Prevention and Treatment of Myopia Eye"
-
Novosibirsk、ロシア、630099
- Joint Stock Company Medical Center "AVICENNA"
-
Omsk、ロシア、644013
- BHI of Omsk region "Clinical Oncology Dispensary"
-
Omsk、ロシア、644024
- Clinicodiagnostic Center "Ultramed"
-
Omsk、ロシア、644070
- Medical center "Intervzglyad"
-
Saint Petersburg、ロシア、191015
- FSBI of Higher Education " North-Western Medical University n.a.I.I. Mechnikov '' of MoH RF
-
Saint Petersburg、ロシア、195067
- FSBI of Higher Education "North-Western Medical University n.a.I.I. Mechnikov'' of MoH RF
-
Stavropol、ロシア、355017
- Autonomous Noncommercial Medical Organization "Stavropol Regional Clinical
-
-
Stavropol Kray
-
Pyatigorsk、Stavropol Kray、ロシア、357502
- LLC "Polyclinic of ultrasonography 4D"
-
-
-
-
Free State
-
Bloemfontein、Free State、南アフリカ、9301
- Dr W Simmonds (Gastroenterology Department)
-
-
Gauteng
-
Benoni、Gauteng、南アフリカ、1501
- Worthwhile Clinical Trials
-
Benoni、Gauteng、南アフリカ、1500
- Dr K Rahman (OTC and Opthalmoscopy)
-
Benoni、Gauteng、南アフリカ、1500
- Lakeview Hospital radiology (Radiology)
-
Benoni、Gauteng、南アフリカ、1500
- Worthwhile Clinical trials (PFT)
-
Centurion、Gauteng、南アフリカ、0157
- Dr E Meyer & Partners, Centurion Eye Hospital (OTC and Opthalmoscopy)
-
Centurion、Gauteng、南アフリカ、0157
- Dr Jorg Reichenberger (Endoscopy)
-
Centurion、Gauteng、南アフリカ、0157
- Drs Burger Radiologists Inc (X-ray/CT)
-
Centurion、Gauteng、南アフリカ、0157
- Johese Clinical Research, Unitas Hospital
-
Johannesburg、Gauteng、南アフリカ、2193
- Wits Clinical Research
-
Kempton Park、Gauteng、南アフリカ、1619
- Clinresco Centres (Pty) Ltd
-
Kempton Park、Gauteng、南アフリカ、1619
- Burger Radiology (Radiology)
-
Kempton Park、Gauteng、南アフリカ、1619
- Dr KJP Lubuya (OCT and Opthalmology)
-
Kempton Park、Gauteng、南アフリカ、1619
- Prof O Mwantembe (Endoscopy)
-
Pretoria、Gauteng、南アフリカ、0002
- Emmed Research
-
Springs、Gauteng、南アフリカ、1559
- Dr K Rahman(OTC and Opthalmoscopy)
-
Sunninghill、Gauteng、南アフリカ、2196
- Dr I Moola (Endoscopy)
-
-
Western Cape
-
Cape Town、Western Cape、南アフリカ、7405
- Dr Peter Chapman (PFT + DLCO)
-
Cape Town、Western Cape、南アフリカ、7441
- Dr Chris Stander (OCT)
-
Cape Town、Western Cape、南アフリカ、7441
- Morton & Partners Radiologists (Radiology)
-
Cape Town、Western Cape、南アフリカ、7441
- Spoke Research Inc. Room 109
-
-
-
-
Chiba
-
Kashiwa-shi、Chiba、日本、277-0871
- Kokikai Tsujinaka Hospital Kashiwanoha
-
Nagareyama-shi、Chiba、日本、270-0116
- Ishii Eye Clinic
-
-
Fukuoka
-
Kitakyushu-shi、Fukuoka、日本、807-8555
- Hospital of the University of Occupational and Environmental Health
-
Kitakyusyu-shi、Fukuoka、日本、802-8561
- Kitakyushu Municipal Medical Center
-
-
Ibaraki
-
Toride-shi、Ibaraki、日本、302-0014
- Matsumoto Eye Clinic
-
-
Kagoshima-ken
-
Kagoshima、Kagoshima-ken、日本、892-0846
- Sameshima Hospital
-
Kagoshima、Kagoshima-ken、日本、892-0824
- Jiaikai Idzuro Imamura Hospital
-
Kagoshima、Kagoshima-ken、日本、890-0062
- Kagoshima Kouseiren Hospital
-
Kagoshima、Kagoshima-ken、日本、892-0825
- Sameshima Eye Clinic
-
-
Kumamoto
-
Kumamoto、Kumamoto、日本、861-8520
- Japanese Red Cross Kumamoto Hospital
-
-
Saga-ken
-
Saga、Saga-ken、日本、849-8501
- Saga University Hospital
-
-
Tokyo
-
Shinjuku-ku、Tokyo、日本、169-0073
- Japan Community Health Care Organization Tokyo Yamate Medical Center
-
-
-
-
-
Daegu、韓国、41404
- Kyungpook National University Chilgok Hospital
-
Daegu、韓国、41944
- Kyungpook National University Hospital
-
Daegu、韓国、41944
- Endoscopy Facility in kyungpook National University Hospital
-
Daegu、韓国、41944
- OCT Facility In kyungpook National University Hospital
-
Daegu、韓国、41944
- PFT Facility in Kyungpook National University Hospital
-
Daejeon、韓国、34943
- The Catholic University of Korea, Daejeon ST. Mary's Hospital
-
Incheon、韓国、21565
- Gachon University Gil Medical Center
-
Seongnam-si、韓国、13496
- CHA University Bundang CHA Hospital
-
Seoul、韓国、06273
- Gangnam Severance Hospital, Yonsei University Health System
-
Seoul、韓国、06973
- Chung-Ang University Hospital
-
Seoul、韓国、02447
- Kyunghee University Medical Center
-
-
Gyeonggi-do
-
Goyang-si、Gyeonggi-do、韓国、10326
- Dongguk University Ilsan Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
説明
すべてのサブスタディに適用される適格基準:
包含基準:
- 18~80歳の男女、
- -書面によるインフォームドコンセントまたは同意を提供し、プロトコル評価のスケジュールに準拠する能力
- -クローン病(CD)と診断された ≥ 3ヶ月
- スクリーニング時に中程度から重度の活動性 CD を持っている
-CDの治療のための以下の治療法の1つ以上に対する不十分な反応(すなわち、一次非反応)、反応の喪失、または不耐性を示した:
- 経口コルチコステロイド(例,プレドニゾンまたは同等のブデソニド)
- 免疫抑制剤(例、アザチオプリン[AZA]、6メルカプトプリン[6-MP]、またはメトトレキサート[MTX])
- 腫瘍壊死因子アルファ(TNFα)拮抗薬(例、インフリキシマブ、アダリムマブ、セルトリズマブ ペゴル、またはバイオシミラー)
- インテグリン受容体拮抗薬(例、ベドリズマブ)
- インターロイキン-12/-23拮抗薬(例、ウステキヌマブ)
- -出産の可能性のある女性は妊娠していない必要があります
- 出産の可能性のある女性と男性は避妊を使用する必要があります
除外基準:
- -CDの治療のために市販されている2つ以上のクラスの生物製剤(すなわち、TNFαアンタゴニスト、インターロイキン12/23アンタゴニスト、およびインテグリン受容体アンタゴニスト)の薬剤に対する不十分な反応(すなわち、一次非反応)の病歴。
- -潰瘍性大腸炎、不定性大腸炎、顕微鏡的大腸炎、虚血性大腸炎、放射線性大腸炎、憩室性疾患関連大腸炎、中毒性巨大結腸、または活動性感染性大腸炎があるか、スクリーニングでClostridioides difficile毒素の検査が陽性。
- -機能的または術後の短腸症候群、または関連する合併症があり、手術が必要になるか、有効性評価に干渉する可能性があります
- -無作為化の8週間前までに腹腔内膿瘍の外科的治療を受けたか、無作為化の4週間前までに肛門周囲膿瘍の外科的治療を受けた。
- -無作為化の24週間前までに腸切除を受けたか、無作為化の12週間前までに他の腹腔内手術を受けた。
- 回腸造瘻または結腸造瘻を行ってください。
サブスタディ 3 の選択基準:
- サブスタディ 1 およびサブスタディ 2 の延長導入期間に入った参加者は、延長導入を完了している必要があります - 第 6 週の訪問
サブスタディ 4 の選択基準:
-参加者は、サブスタディ3の52週目の訪問またはサブスタディAの66週目の訪問を完了している必要があります
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
プラセボコンパレーター:プラセボ
|
エトラシモド マッチング プラセボ タブレットを 1 日 1 回経口摂取。
|
|
実験的:エトラシモド用量A
|
用量 A を 1 日 1 回経口摂取。
他の名前:
用量 B を 1 日 1 回経口摂取。
他の名前:
|
|
実験的:エトラシモド用量B
|
用量 A を 1 日 1 回経口摂取。
他の名前:
用量 B を 1 日 1 回経口摂取。
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants With Endoscopic Response by Simple Endoscopic Score in Crohn's Disease (SES-CD) at Week 14: SSA
時間枠:Week 14 of SSA
|
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from study baseline in SES-CD.
SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum.
Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers.
Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%.
Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%.
Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed.
Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
|
Week 14 of SSA
|
|
Percentage of Participants With Endoscopic Response by SES-CD at Week 14: SS1
時間枠:Week 14 of SS1
|
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from study baseline in SES-CD.
SES-CD consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum.
Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers.
Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%.
Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%.
Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple can be passed, 3= cannot be passed.
Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
Multiple imputation (MI) method used; percentage calculated based on average response rate from MI datasets.
|
Week 14 of SS1
|
|
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Responder Cohort
時間枠:Week 52 of study
|
Clinical remission was considered as CDAI score <150.
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); hematocrit (HCT): 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
|
Week 52 of study
|
|
Percentage of Participants With Clinical Remission by CDAI at Week 52: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Clinical remission was considered as CDAI score <150.
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
|
Week 52 of study
|
|
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Responder Cohort
時間枠:Week 52 of study
|
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD.
SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon; rectum.
Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers.
Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30%, 3= >30%.
Affected surface score: 0= unaffected segment, 1= <50%,2= 50%-75%,3= >75%.
Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed.
Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
|
Week 52 of study
|
|
Percentage of Participants With Endoscopic Response by SES-CD at Week 52: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD.
SES-CD consisted of composite score based on size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right, transverse; left colon; rectum.
Size of ulcers score: 0=none, 1=aphthous ulcers,2=large ulcers,3=very large ulcers.
Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30%, 3= >30%.
Affected surface score: 0= unaffected segment, 1= <50%,2= 50%-75%,3= >75%.
Presence of narrowing score: 0=none,1=single, can be passed, 2=multiple, can be passed,3=cannot be passed.
Total SES CD=sum of each domain score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score= more severe disease.
|
Week 52 of study
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants With Clinical Remission by CDAI at Week 14: SSA
時間枠:Week 14 of SSA
|
Clinical remission was considered as CDAI score <150.
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
|
Week 14 of SSA
|
|
Change From Baseline in SES-CD Score at Week 14: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 bowel segments: ileum; right; transverse; left colon and rectum.
Size of ulcers score: 0= none, 1= aphthous ulcers, 2= large ulcers and 3= very large ulcers.
Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%.
Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%.
Presence of narrowing score: 0= none, 1= single, can be passed, 2= multiple, can be passed, 3= cannot be passed.
Total SES-CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease) to 60 (severe disease), higher score indicated more severe disease.
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
|
Change From Baseline in CDAI Score at Week 14: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
|
Plasma Concentration of Etrasimod at 4 Hours Post-dose: SSA
時間枠:4 hours post-dose on Day 1
|
The plasma concentration of etrasimod at 4 hours post-dose has been reported in this outcome measure.
|
4 hours post-dose on Day 1
|
|
Steady State Trough Concentration (Ctrough,ss) of Etrasimod From Week 2 to Week 14: SSA
時間枠:From Week 2 to Week 14
|
The average steady-state Ctrough for Week 2 through 14 was calculated based on individual Ctrough data from Week 2, Week 6 and Week 14.
|
From Week 2 to Week 14
|
|
Change From Baseline in Absolute Lymphocyte Count (ALC) at Week 14 in Induction Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
|
|
Percent Change From Baseline in ALC at Week 14 in Induction Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
|
|
Change From Baseline in ALC at Week 66 in Extension Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
|
|
Percent Change From Baseline in ALC at Week 66 in Extension Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
|
|
Change From Baseline in Fecal Calprotectin (FCP) Concentration at Week 14 in Induction Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
|
|
Percent Change From Baseline in FCP Concentration at Week 14 in Induction Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
|
|
Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
|
|
Percent Change From Baseline in FCP Concentration at Week 66 in Extension Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
|
|
Change From Baseline in C-Reactive Protein (CRP) at Week 14 in Induction Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
|
|
Percent Change From Baseline in CRP at Week 14 in Induction Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 14 of SSA
|
|
|
Change From Baseline in CRP at Week 66 in Extension Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
|
|
Percent Change From Baseline in CRP at Week 66 in Extension Period: SSA
時間枠:Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
Baseline (last measurement taken prior to the first dose of study treatment) and Week 66 of SSA
|
|
|
Percentage of Participants With Clinical Remission by CDAI at Week 14: SS1
時間枠:Week 14 of SS1
|
Clinical remission was considered as CDAI score <150.
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
MI method was used; percentage was calculated based on average response rate from MI datasets.
|
Week 14 of SS1
|
|
Percentage of Participants With Clinical Remission by Patient Reported Outcomes 2 (PRO2) at Week 14: SS1
時間枠:Week 14 of SS1
|
Clinical remission was defined as PRO2 score <8.
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
MI method was used; percentage was calculated based on average response rate from MI datasets.
|
Week 14 of SS1
|
|
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Responder Cohort
時間枠:Week 52 of study
|
Clinical remission was CDAI score <150.
CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score: sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease.
SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
|
Week 52 of study
|
|
Percentage of Participants With Clinical Remission by CDAI at Week 52 Among Participants With Clinical Remission by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Clinical remission was CDAI score <150.
CDAI was a composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT: 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score: sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores= more severe disease.
SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
|
Week 52 of study
|
|
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Responder Cohort
時間枠:Week 52 of study
|
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD.
SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum.
Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers.
Ulcerated surface score: 0= none,1= <10%, 2= 10%-30%, 3= >30%.
Affected surface score: 0= unaffected segment, 1= <50%, 2= 50%-75%,3= >75%.
Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed.
Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease.
SS3 Baseline was last non-missing measurement taken prior to FMD date.
|
Week 52 of study
|
|
Percentage of Participants With Endoscopic Response at Week 52 Among Participants With Endoscopic Response at SS3 Baseline: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD.
SES-CD= composite score based on 4 components: size of ulcers, ulcerated surface, affected surface, presence of narrowing in 5 segments: ileum; right; transverse; left colon; rectum.
Size of ulcers score: 0=none,1= aphthous ulcers, 2= large ulcers, 3= very large ulcers.
Ulcerated surface score: 0= none,1= <10%, 2= 10%-30%, 3= >30%.
Affected surface score: 0= unaffected segment, 1= <50%, 2= 50%-75%,3= >75%.
Presence of narrowing score: 0= none,1= single, can be passed, 2= multiple can be passed, 3= can't be passed.
Total SES CD=sum of component scores for 5 bowel segments and ranged from 0 (no disease) - 60 (severe disease), higher score indicated more severe disease.
SS3 Baseline was last non-missing measurement taken prior to FMD date.
|
Week 52 of study
|
|
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Responder Cohort
時間枠:Week 52 of study
|
Corticosteroid-free remission: CDAI score <150 without receiving corticosteroids for >=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline).
CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10.
Total CDAI score=sum of variable scores*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease.
SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
|
Week 52 of study
|
|
Percentage of Participants With Corticosteroid-Free Clinical Remission by CDAI at Week 52 Among Participants Receiving Corticosteroids at SS3 Baseline: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Corticosteroid-free remission: CDAI score <150 without receiving corticosteroids for >=8 weeks prior to Week 52 (for participants receiving corticosteroids at baseline).
CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid stools; extent of abdominal pain from 0 (none)-3 (severe); general well-being from 0 (generally well)-4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women; percentage deviation from standard weight, lower bound -10.
Total CDAI score=sum of variable scores*weighting factor and was from 0 (no disease)-600 (severe disease), higher score indicated more severe disease.
SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
|
Week 52 of study
|
|
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Responder Cohort
時間枠:Week 52 of study
|
Endoscopic remission: SES-CD score <=4 and at least 2-point reduction from baseline with no sub-score >1.
SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum.
Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers.
Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%.
Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%.
Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed.
Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
|
Week 52 of study
|
|
Percentage of Participants With Endoscopic Remission at Week 52: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Endoscopic remission: SES-CD score <=4 and at least 2-point reduction from baseline with no sub-score >1.
SES-CD consisted of a composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum.
Size of ulcers score: 0=none, 1=aphthous ulcers, 2=large ulcers and 3=very large ulcers.
Ulcerated surface score: 0= none, 1= <10%, 2= 10% - 30% and 3= >30%.
Affected surface score: 0= unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%.
Presence of narrowing score: 0=none, 1= single, can be passed, 2=multiple, can be passed, 3= cannot be passed.
Total SES CD=sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
|
Week 52 of study
|
|
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
時間枠:Week 52 of study
|
Clinical remission was defined as PRO2 score <8.
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
|
Week 52 of study
|
|
Percentage of Participants With Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Clinical remission was defined as PRO2 score <8.
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
|
Week 52 of study
|
|
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Responder Cohort
時間枠:Week 52 of study
|
Clinical response: clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI <150.
CDAI: composite index consisting of weighted scoring of 8 disease activity variables.
Total CDAI: sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease.
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from baseline in SES-CD.
SES-CD comprised of 4 components assessed for 5 bowel segments.
Each component score ranged from 0-3, higher scores indicated more severe condition.
Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease.
Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
|
Week 52 of study
|
|
Percentage of Participants With Clinical Response or Endoscopic Response at Week 52: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Clinical response: clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI=CDAI <150.
CDAI: composite index consisting of weighted scoring of 8 disease activity variables.
Total CDAI: sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), higher scores indicated more severe disease.
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from baseline in SES-CD.
SES-CD comprised of 4 components assessed for 5 bowel segments.
Each component score ranged from 0-3, higher scores indicated more severe condition.
Total SES CD: sum of each component score of 5 bowel segments and ranged from 0 (no D) - 60 (severe disease), higher score indicated more severe disease.
Percentage of participants with clinical response or endoscopic response at Week 52 is reported.
|
Week 52 of study
|
|
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
時間枠:Baseline, study Weeks 20, 28, 36, 44, 52
|
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 20, 28, 36, 44, 52
|
|
Change From Baseline in CDAI Score at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
時間枠:Baseline, study Weeks 20, 28, 36, 44, 52
|
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
SS3 Baseline was last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 20, 28, 36, 44, 52
|
|
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Responder Cohort
時間枠:Week 52 of study
|
Clinical Response was clinical remission by CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI <150.
CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score= sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease.
SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
|
Week 52 of study
|
|
Percentage of Participants With Clinical Response by CDAI at Week 52 Among Participants With Clinical Response by CDAI at SS3 Baseline: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Clinical Response was clinical remission by CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission CDAI= CDAI <150.
CDAI: composite index consisting of weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none)-3 (severe); general well-being rating assessed from 0 (generally well) - 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide/opiates for diarrhea; presence of an abdominal mass (0=none, 2=questionable, 5=definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score= sum of variable scores*weighting factor and ranged from 0 (no disease) - 600 (severe disease), where higher scores indicated more severe disease.
SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
|
Week 52 of study
|
|
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Responder Cohort
時間枠:Baseline, study Weeks 28 and 52
|
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms.
Each module ranged from 0 to 16, where higher scores indicated more severe disease.
SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 28 and 52
|
|
Change From Baseline in Crohn's Disease Patient-Reported Outcomes (CD-PRO) Module Scores at Weeks 28 and 52: SS3 Non-Responder Cohort
時間枠:Baseline, study Weeks 28 and 52
|
The CD-PRO was a validated instrument designed to assess the signs, symptoms, and impact of CD through 6 modules: Systemic Symptoms, Coping Strategies, Daily Life Impact, Emotional Impact, Bowel Signs and Symptoms and Functional Symptoms.
Each module ranged from 0 to 16, where higher scores indicated more severe disease.
SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 28 and 52
|
|
Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) at Weeks 28 and 52: SS3 Responder Cohort
時間枠:Baseline, study Weeks 28 and 52
|
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD.
Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life.
The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life.
SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 28 and 52
|
|
Change From Baseline in IBDQ at Weeks 28 and 52: SS3 Non-Responder Cohort
時間枠:Baseline, study Weeks 28 and 52
|
The IBDQ was a validated 32 item questionnaire used to assess health related quality of life in participants with IBD.
Response to each of the questions ranged from 1 to 7 where higher scores indicated better quality of life.
The total IBDQ scores were calculated as sum of individual item scores and ranged from 32 (very poor health-related quality of life) to 224 (perfect health-related quality of life) where higher scores indicated better quality of life.
SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 28 and 52
|
|
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) at Weeks 28 and 52: SS3 Responder Cohort
時間枠:Baseline, study Weeks 28 and 52
|
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality.
The 8 domains are combined to form 2 component scores mental (MCS) and physical (PCS).
MCS consisted of social functioning, vitality, mental health, and role-emotional scales.
PCS consisted of physical functioning, bodily pain, role-physical, and general health scales.
Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status.
SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 28 and 52
|
|
Change From Baseline in SF-36 at Weeks 28 and 52: SS3 Non-Responder Cohort
時間枠:Baseline, study Weeks 28 and 52
|
The SF-36 was a health-related survey that assessed participant's health status and consisted of 36 questions measuring 8 health domains: physical functioning, bodily pain, role limitations due to physical problems, role limitations due to emotional problems, general health perceptions, mental health, social function and vitality.
The 8 domains are combined to form 2 component scores MCS and PCS.
MCS consisted of social functioning, vitality, mental health, and role-emotional scales.
PCS consisted of physical functioning, bodily pain, role-physical, and general health scales.
Each domain was scored by summing the individual items and transforming the total SF-36 scores into a 0 to 100 scale with higher scores indicating better health status.
SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 28 and 52
|
|
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at Weeks 28 and 52: SS3 Responder Cohort
時間枠:Baseline, study Weeks 28 and 52
|
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue.
Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much).
Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).
SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 28 and 52
|
|
Change From Baseline in FACIT-F at Weeks 28 and 52: SS3 Non-Responder Cohort
時間枠:Baseline, study Weeks 28 and 52
|
The FACIT-F was a participant completed questionnaire consisting of 13 items that assess fatigue.
Participants responded to each item on a 5-point scale based on their experience of fatigue during the past 7 days (0 = not at all; 1 = a little bit; 2 =somewhat; 3 = quite a bit; 4 = very much).
Instrument scoring yielded a total FACIT-F score range from 0 to 52 (negatively worded items were reversed during analysis), with higher scores representing better participant status (less fatigue).
SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 28 and 52
|
|
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at SS3 Baseline: SS3 Responder Cohort
時間枠:Week 52 of study
|
Clinical remission was defined as PRO2 score <8.
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
|
Week 52 of study
|
|
Percentage of Participants With Clinical Remission by PRO2 at Week 52 Among Participants With Clinical Remission by PRO2 at Study Entry: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Clinical remission was defined as PRO2 score <8.
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
|
Week 52 of study
|
|
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Responder Cohort
時間枠:Baseline, study Weeks 20, 28, 36, 44 and 52
|
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 20, 28, 36, 44 and 52
|
|
Change From Baseline in PRO2 Scores at Weeks 20, 28, 36, 44 and 52: SS3 Non-Responder Cohort
時間枠:Baseline, study Weeks 20, 28, 36, 44 and 52
|
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
SS3 Baseline was defined as last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline, study Weeks 20, 28, 36, 44 and 52
|
|
Time to Remission by PRO2 and FCP Concentrations: SS3 Responder Cohort
時間枠:From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
|
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization.
Clinical remission by PRO2 was defined as PRO2 score <8.
Normalization of FCP was defined as FCP <=150 milligrams per kilogram.
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
|
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
|
|
Time to Remission by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
時間枠:From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
|
Time to remission by PRO2 and FCP concentrations was defined as time to onset of clinical remission by PRO2 and FCP normalization.
Clinical remission by PRO2 was defined as PRO2 score <8.
Normalization of FCP was defined as FCP <=150 milligrams per kilogram.
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Participants who did not achieve remission or discontinued from study were censored at 7 days after last dose of study drug.
|
From first maintenance dose in SS3 until date of clinical remission and FCP normalization or censoring date (maximum up to 42 weeks)
|
|
Time to Response by PRO2 and FCP Concentrations: SS3 Responder Cohort
時間枠:From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
|
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization.
Clinical response by PRO2: clinical remission by PRO2 or >= 8-point decrease from baseline in PRO2 score.
Clinical remission by PRO2: PRO2 score <8.
Normalization of FCP: FCP <=150 milligrams per kilogram.
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
|
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
|
|
Time to Response by PRO2 and FCP Concentrations: SS3 Non-Responder Cohort
時間枠:From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
|
Time to response by PRO2 and FCP concentrations: time to onset of PRO2 response and FCP normalization.
Clinical response by PRO2: clinical remission by PRO2 or >= 8-point decrease from baseline in PRO2 score.
Clinical remission by PRO2: PRO2 score <8.
Normalization of FCP: FCP <=150 milligrams per kilogram.
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
Participants who did not achieve response or discontinued from study were censored at 7 days after last dose of study drug.
|
From first maintenance dose in SS3 until date of clinical response and FCP normalization or censoring date (maximum up to 42 weeks)
|
|
Change From Baseline in SES-CD Score at Week 52: SS3 Responder Cohort
時間枠:Baseline and Week 52 of study
|
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum.
Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers.
Ulcerated surface score: 0=none, 1= <10%, 2= 10% - 30% and 3= >30%.
Affected surface score: 0=unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%.
Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed.
Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline and Week 52 of study
|
|
Change From Baseline in SES-CD Score at Week 52: SS3 Non-Responder Cohort
時間枠:Baseline and Week 52 of study
|
SES-CD was an endoscopic grading system which consisted of composite score based on 4 components: size of ulcers, ulcerated surface, affected surface and presence of narrowing assessed in 5 segments: ileum; right; transverse; left colon and rectum.
Size of ulcers score: 0= none, 1= aphthous ulcers, 2=large ulcers and 3=very large ulcers.
Ulcerated surface score: 0=none, 1= <10%, 2= 10% - 30% and 3= >30%.
Affected surface score: 0=unaffected segment, 1= <50%, 2= 50% - 75%, and 3= >75%.
Presence of narrowing score: 0=none, 1=single, can be passed, 2=multiple can be passed, 3=cannot be passed.
Total SES CD= sum of each component score for all 5 bowel segments and ranged from 0 (no disease)-60 (severe disease), higher score indicated more severe disease.
SS3 Baseline= last non-missing measurement taken prior to date of FMD of SS3.
|
Baseline and Week 52 of study
|
|
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
時間枠:Week 52 of study
|
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD.
SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition.
Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease.
Clinical remission by PRO2: PRO2 score <8.
PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI.
Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days.
Stool frequency was number of liquid or soft stools each day for 7 days.
Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
|
Week 52 of study
|
|
Percentage of Participants With Endoscopic Response and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Endoscopic response: SES-CD score <=4 and at least 2-point reduction from baseline with no subscore >1 or >=50% decrease from parent study (SS1) baseline in SES-CD.
SES-CD had 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores=more severe condition.
Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0-60, higher score=more severe disease.
Clinical remission by PRO2: PRO2 score <8.
PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI.
Abdominal pain graded from 0 (none)-3 (severe) each day for 7 days.
Stool frequency was number of liquid or soft stools each day for 7 days.
Total PRO2 score calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
PRO2 score had minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
|
Week 52 of study
|
|
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Responder Cohort
時間枠:Week 52 of study
|
Endoscopic remission: SES-CD <=4 and at least 2-point reduction from baseline with no sub-score >1.
SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition.
Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease.
Clinical remission by PRO2 was defined as PRO2 score <8.
PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
Stool frequency was number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
|
Week 52 of study
|
|
Percentage of Participants With Endoscopic Remission and Clinical Remission by PRO2 at Week 52: SS3 Non-Responder Cohort
時間枠:Week 52 of study
|
Endoscopic remission: SES-CD <=4 and at least 2-point reduction from baseline with no sub-score >1.
SES-CD comprised of 4 components assessed for 5 bowel segments where, each component score ranged from 0 to 3, higher scores indicated more severe condition.
Total SES CD score was determined by sum of each component score for all 5 bowel segments and ranged from 0 to 60, higher score indicated more severe disease.
Clinical remission by PRO2 was defined as PRO2 score <8.
PRO2 was patient-reported outcome measure based on abdominal pain and stool frequency components of CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
Stool frequency was number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
PRO2 score had a minimum score of 0 and had no upper bound, with higher score indicating more frequent stools and more severe abdominal pain.
|
Week 52 of study
|
|
Number of Participants According to Markedly Abnormal Criteria for Electrocardiogram (ECG) Parameters: SS4
時間枠:Baseline, Weeks 52, and 104 of SS4
|
Pre-defined markedly abnormal criteria for ECG parameters included: QT interval: >500 (milliseconds [msec]); change from SS4 baseline >30 msec and change from SS4 baseline >60 msec.
QT interval corrected using Fridericia's formula (QTcF) (msec): >=450 (male) or >=470 (female) msec; change from SS4 baseline >30 msec; change from SS4 baseline >60 msec.
PR interval (msec): >230 msec.
Only those ECG parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure.
SS4 Baseline was defined as the last non-missing measurement taken up to the date of first dose in the SS4.
|
Baseline, Weeks 52, and 104 of SS4
|
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), TEAEs by Severity and Treatment Related TEAEs: SS3
時間枠:From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
|
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment.
SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant.
AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, Grade(G) 1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment.
Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
|
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
|
|
Number of Participants With TEAEs of Special Interest: SS3
時間枠:From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
|
The TEAEs of special interest included: cardiovascular events (bradycardia, atrioventricular [AV] conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction [forced expiratory volume in 1 second, and forced vital capacity], decreased gas exchange [diffusing capacity of the lung for carbon monoxide]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies.
Number of participants with any TEAEs of special interest were reported in this outcome measure.
|
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
|
|
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS3
時間枠:From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
|
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (<0.8*LLN);
Ery.
Volume, Hemoglobin,Mean Corpuscular HGB Concentration <0.8*LLN or >1.5*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (>1.2*ULN),
Prothrombin Time(>1.1*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (>3.0*ULN);
Albumin, Urate (<0.8*LLN and >1.2*ULN; Urea Nitrogen,Creatinine Cholesterol >1.3*ULN; Cholesterol <0.8*LLN or >1.2*LLN, Triglycerides,Potassium,Calcium < 0.9x LLN & >1.1x ULN; Bicarbonate, Glucose, Creatine Kinase.
Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite >=1; Leukocyte Erythrocytes, Leukocytes >=20; Epithelial Cells>=6, Hyaline Cast>1; Bacteria>20.
Number of participants with any laboratory abnormality meeting specified criteria is included.
|
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 38 weeks; maximum follow-up: 42 weeks)
|
|
Number of Participants With TEAEs, SAEs, TEAEs by Severity and Treatment Related TEAEs: SS4
時間枠:From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
|
AE: any untoward medical occurrence that did not necessarily have a causal relationship with treatment.
SAE: an AE that met one of the following criteria: resulted in death; was life-threatening; required inpatient or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect or medically significant.
AEs were graded by the National Cancer Institute Common Terminology Criteria for AE version 5 where, G1: mild AE; G2: moderate; G3: severe; G4: life-threatening consequences, urgent intervention indicated; G5: death related to AE. AE was considered TEAE if it started or worsened in severity on or after the first dose of study treatment.
Treatment related AEs were AEs that were related to the study treatment and relatedness was judged by investigator.
|
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
|
|
Number of Participants With TEAEs of Special Interest: SS4
時間枠:From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
|
The TEAEs of special interest included: cardiovascular events (bradycardia, AV conduction delay, and hypertension); macular edema; pulmonary disorders (airflow obstruction [forced expiratory volume in 1 second, and forced vital capacity], decreased gas exchange [diffusing capacity of the lung for carbon monoxide]); infections (severe infections, opportunistic infections, and herpes simplex and herpes zoster); liver injury (liver transaminases elevation, and bilirubin elevation); posterior reversible encephalopathy syndrome; and malignancies.
Number of participants with any TEAEs of special interest were reported in this outcome measure.
|
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
|
|
Number of Participants With Clinically Meaningful Changes in Laboratory Parameters: SS4
時間枠:From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
|
Clinically meaningful laboratory abnormalities:Hemoglobin, Hematocrit, Erythrocytes (<0.8*LLN);
Ery.
Volume, Hemoglobin,Mean Corpuscular HGB Concentration <0.8*LLN or >1.5*LLN;Reticulocytes, Leukocytes, Lymphocytes, Neutrophils, Neutrophils, Basophils, Eosinophils, Monocytes (>1.2*ULN),
Prothrombin Time(>1.1*ULN).Clinical Chemistry: Bilirubin, Direct Bilirubin, Indirect Bilirubin (1.5*ULN), Aspartate Aminotransferase, Alanine Aminotransferase, Gamma Glutamyl Transferase, Alkaline Phosphatase (>3.0*ULN);
Albumin, Urate (<0.8*LLN and >1.2*ULN; Urea Nitrogen,Creatinine Cholesterol >1.3*ULN; Cholesterol <0.8*LLN or >1.2*LLN, Triglycerides,Potassium,Calcium < 0.9x LLN & >1.1x ULN; Bicarbonate, Glucose, Creatine Kinase.
Urinalysis: Glucose, Ketones, Protein, Hemoglobin, Urobilinogen, Bilirubin, Nitrite >=1; Leukocyte Erythrocytes, Leukocytes >=20; Epithelial Cells>=6, Hyaline Cast>1; Bacteria>20.
Number of participants with any laboratory abnormality meeting specified criteria is included.
|
From first dose of study treatment (Day 1) up to 4 weeks post last dose of study treatment (maximum treatment exposure: 166.3 weeks; maximum follow-up: 170.3 weeks)
|
|
Number of Participants According to Markedly Abnormal Criteria for Vital Signs: SS4
時間枠:Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
|
Pre-defined markedly abnormal criteria for vital signs included: Systolic blood pressure (millimeters of mercury [mmHg]): low: <=90 mmHg and high: >150 mmHg.
Diastolic blood pressure (mmHg): low: <=50 mmHg and high: >90 mmHg.
Heart rate (beats per minute [bpm]): low: <40 bpm, <50 bpm and high: >100 bpm.
Only those vital signs parameters in which at least 1 participant in any of the reporting arm had markedly abnormal criteria are reported in this outcome measure.
SS4 baseline=the last non-missing measurement taken up to the date of first dose in the SS4.
|
Baseline, Weeks 1, 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
|
|
Percentage of Participants With Clinical Remission by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
時間枠:Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
|
Clinical remission was considered as CDAI score <150.
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
|
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
|
|
Percentage of Participants With Clinical Response by CDAI at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
時間枠:Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
|
Clinical Response was defined as having clinical remission CDAI or >=100-point decrease from baseline in CDAI score where, clinical remission was considered as CDAI <150.
CDAI was a composite index consisting of a weighted scoring of 8 disease activity variables: number of liquid or soft stools; extent of abdominal pain graded from 0 (none) to 3 (severe); general well-being rating assessed from 0 (generally well) to 4 (terrible); presence of complications; taking diphenoxylate/atropine, loperamide or opiates for diarrhea; presence of an abdominal mass (0 as none, 2 as questionable, 5 as definite); HCT 47 in men and 42 in women and percentage deviation from standard weight, lower bound -10.
Total CDAI score was calculated as the sum of variable scores*weighting factor and ranged from 0 (no disease) to 600 (severe disease), where higher scores indicated more severe disease.
|
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
|
|
Percentage of Participants With Clinical Remission by PRO2 at Weeks 12, 24, 36, 52, 64, 76, 88 and 104: SS4
時間枠:Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
|
Clinical remission was defined as PRO2 score <8.
The PRO2 was a patient-reported outcome measure based on abdominal pain and stool frequency components of the CDAI.
The abdominal pain rating was graded from 0 (none) to 3 (severe) each day for 7 days.
The stool frequency was defined as number of liquid or soft stools each day for 7 days.
Total PRO2 score was calculated as the sum of averaged abdominal pain/stool frequency variable scores*weighting factor.
The PRO2 score had a minimum score of 0 and had no upper bound, with a higher score indicating more frequent stools and more severe abdominal pain.
|
Weeks 12, 24, 36, 52, 64, 76, 88 and 104 of SS4
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Pfizer CT.gov Call Center、Pfizer
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- APD334-202
- C5041006 (その他の識別子:Alias Study Number)
- 2024-513569-38-00 (レジストリ識別子:CTIS (EU))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。